mTOR Signaling in CBS/PSP

mTOR Signaling in CBS/PSP

Overview

The mechanistic target of rapamycin (mTOR) pathway serves as a central integrator of cellular growth, protein synthesis, autophagy, and metabolic homeostasis. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of mTOR signaling contributes significantly to neurodegeneration through impaired autophagy, excessive protein synthesis, synaptic dysfunction, and cellular energy mismanagement. This section examines the role of mTOR pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications.

mTOR exists in two structurally and functionally distinct complexes: mTORC1 (mechanistic target of rapamycin complex 1) and mTORC2 (mechanistic target of rapamycin complex 2). While mTORC1 is rapamycin-sensitive and primarily regulates autophagy and protein synthesis, mTORC2 is partially resistant to acute rapamycin treatment and controls cytoskeletal organization, cell survival, and metabolic signaling. Both complexes are relevant to tauopathy pathogenesis.

The mTOR pathway has emerged as a particularly attractive therapeutic target because:

It is hyperactive in tauopathies, creating a pathogenic feedback loop with tau accumulation

Pharmacological inhibition using rapamycin and analogs is clinically feasible

mTOR inhibition simultaneously addresses multiple pathological mechanisms

Preclinical data in tauopathy models is highly promising

The mTOR Signaling Pathway

mTOR Complex 1 (mTORC1)

...

mTOR Signaling in CBS/PSP

Overview

The mechanistic target of rapamycin (mTOR) pathway serves as a central integrator of cellular growth, protein synthesis, autophagy, and metabolic homeostasis. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of mTOR signaling contributes significantly to neurodegeneration through impaired autophagy, excessive protein synthesis, synaptic dysfunction, and cellular energy mismanagement. This section examines the role of mTOR pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications.

mTOR exists in two structurally and functionally distinct complexes: mTORC1 (mechanistic target of rapamycin complex 1) and mTORC2 (mechanistic target of rapamycin complex 2). While mTORC1 is rapamycin-sensitive and primarily regulates autophagy and protein synthesis, mTORC2 is partially resistant to acute rapamycin treatment and controls cytoskeletal organization, cell survival, and metabolic signaling. Both complexes are relevant to tauopathy pathogenesis.

The mTOR pathway has emerged as a particularly attractive therapeutic target because:

It is hyperactive in tauopathies, creating a pathogenic feedback loop with tau accumulation

Pharmacological inhibition using rapamycin and analogs is clinically feasible

mTOR inhibition simultaneously addresses multiple pathological mechanisms

Preclinical data in tauopathy models is highly promising

The mTOR Signaling Pathway

mTOR Complex 1 (mTORC1)

mTORC1 is a rapamycin-sensitive complex comprising mTOR, Raptor (regulatory protein associated with mTOR), mLST8, PRAS40, and DEPTOR. It functions as a central nutrient and growth factor sensor that integrates signals from amino acids, insulin/IGF-1, cellular energy status (AMP/ATP ratio), and stress to regulate cell growth and metabolism[@laplante2012].

Key upstream regulators:

• Amino acids (particularly leucine): Activate mTORC1 through the Rag GTPases
• Insulin/IGF-1 signaling: Activate through PI3K/AKT and ERK pathways
• AMP/ATP ratio: High AMP (low energy) inhibits mTORC1 through AMPK
• Growth factors: Activate through various receptor tyrosine kinases

Major downstream substrates:

• S6K1 (p70 ribosomal protein S6 kinase 1): Phosphorylation promotes protein synthesis through ribosomal protein S6
• 4E-BP1 (eIF4E-binding protein 1): Phosphorylation releases eIF4E to initiate cap-dependent translation
• ULK1 (Unc-51 Like Autophagy Activating Kinase 1): Phosphorylation at Ser757 inhibits autophagy initiation
• TFEB (Transcription Factor EB): Cytoplasmic retention prevents lysosomal biogenesis gene expression
• eIF4G: Direct phosphorylation enhances translation initiation

mTOR Complex 2 (mTORC2)

mTORC2 is partially resistant to acute rapamycin treatment and comprises mTOR, Rictor (rapamycin-insensitive companion of mTOR), mLST8, mSIN1, and Protor. It primarily regulates cytoskeletal organization, cell survival, and metabolism[@oh2011].

Key downstream substrates:

• Akt (PKB): Phosphorylation at Ser473 is required for full Akt activation
• SGK1 (Serum and Glucocorticoid-regulated Kinase 1): Regulates ion transport and cell survival
• PKCα (Protein Kinase C alpha): Controls cytoskeletal dynamics and cell adhesion

Relevance to neurodegeneration:

• mTORC2/Akt signaling is neuroprotective and promotes neuronal survival
• Dysregulation contributes to impaired insulin signaling in the brain
• Chronic rapamycin treatment may inadvertently inhibit mTORC2

mTOR Signaling Cascade

mTOR in Normal Brain Function

Autophagy Regulation

Autophagy (macroautophagy) is the process by which cells degrade and recycle damaged organelles, protein aggregates, and intracellular pathogens. mTORC1 is the primary negative regulator of autophagy in neurons[@rubinsztein2015]:

• Basal autophagy: In healthy neurons, basal autophagy maintains protein homeostasis
• Nutrient sensing: mTORC1 activity decreases during fasting, permitting autophagy
• Aggregate clearance: Autophagy specifically targets protein aggregates that cannot be degraded by the proteasome
• Neuronal uniqueness: Neurons rely heavily on autophagy due to their post-mitotic nature and high metabolic demands

Protein Synthesis and Synaptic Plasticity

mTORC1 regulates local protein synthesis at synapses, which is essential for synaptic plasticity, learning, and memory[@hoeffer2010]:

• dendritic translation: mTORC1 enables synthesis of synaptic proteins near dendritic spines
• Long-term potentiation (LTP): Required for the protein synthesis-dependent late phase of LTP
• Learning and memory: mTOR signaling in the hippocampus is critical for memory formation
• Synaptic homeostasis: Balances synaptic strength through regulated protein turnover

Metabolic Regulation

mTORC1 integrates metabolic signals to coordinate cellular responses:

• Lipid synthesis: Promotes fatty acid and cholesterol synthesis when nutrients are abundant
• Glycolysis: Enhances glycolytic flux through HIF-1α stabilization
• Mitochondrial function: Coordinates mitochondrial biogenesis and dynamics
• Amino acid sensing: Directs amino acids toward protein synthesis or degradation

mTOR Dysregulation in CBS/PSP

Hyperactivation of mTORC1

Multiple studies demonstrate mTORC1 pathway hyperactivation in CBS/PSP brains[@ferrington2021]:

Increased mTOR phosphorylation: Elevated p-mTOR (Ser2448) in affected brain regions

Enhanced S6K1 activity: Increased p-S6K1 and downstream p-S6 ribosomal protein

Elevated 4E-BP1 phosphorylation: Enhanced cap-dependent translation initiation

Correlation with tau pathology: mTOR activity correlates with 4R tau burden

The motor cortex, basal ganglia, and brainstem regions prominently affected in CBS and PSP show particularly elevated mTORC1 signaling. Immunohistochemical studies demonstrate increased p-S6 immunoreactivity in neurons containing tau aggregates.

Autophagy Impairment

mTORC1 hyperactivation creates a critical bottleneck in autophagy[@nixon2013]:

• ULK1 inhibition: Phosphorylation at Ser757 prevents autophagy initiation
• TFEB sequestration: Cytoplasmic retention prevents lysosomal biogenesis
• Impaired aggregate clearance: Reduced autophagic flux allows tau accumulation
• Lysosomal dysfunction: Downstream lysosomal pathway deficits compound the problem

The combination of mTORC1-driven autophagy inhibition and inherent lysosomal dysfunction in tauopathies creates a particularly severe impairment of protein quality control.

Relationship to Tau Pathology

mTOR signaling and tau pathology engage in a pathogenic positive feedback loop[@wang2016]:

Synaptic Dysfunction

mTOR dysregulation contributes to synaptic deficits in CBS/PSP:

• Excessive translation: Hyperactive mTORC1 leads to dysregulated synaptic protein synthesis
• Impaired plasticity: Abnormal mTOR signaling disrupts LTP and learning
• Synaptic loss: Correlates with cognitive decline in tauopathies
• Network hyperexcitability: mTOR dysregulation may contribute to seizures in some patients

Regional Vulnerability

The pattern of mTOR dysregulation in CBS/PSP follows the regional distribution of tau pathology:

• Motor cortex: Severe mTORC1 hyperactivation in CBS
• Basal ganglia: Elevated signaling in both CBS and PSP
• Brainstem: Significant changes in PSP, particularly in the midbrain
• Substantia nigra: Contributes to dopaminergic neuron vulnerability
• Hippocampus: Memory circuitry affected, correlating with cognitive impairment

Therapeutic Implications

Rapamycin and Rapalogs

Rapamycin (sirolimus) and related rapalogs (temsirolimus, everolimus) are allosteric mTORC1 inhibitors that have shown promise in tauopathy models[@stallings2021]:

Mechanisms of neuroprotection:

• Autophagy induction: ULK1 activation and TFEB nuclear translocation
• Tau clearance: Enhanced autophagic degradation of phosphorylated tau
• Neuroinflammation reduction: mTORC1 inhibition in microglia reduces pro-inflammatory responses
• Anti-aging effects: mTOR inhibition mimics caloric restriction, extending healthspan

Clinical considerations:

• Dosing: Low-dose intermittent dosing may optimize benefit/risk
• BBB penetration: Rapamycin crosses the blood-brain barrier
• Immunosuppression: Risk of infections with chronic use
• Metabolic effects: May cause hyperlipidemia and glucose intolerance

ATP-Competitive mTOR Inhibitors

Second-generation mTOR inhibitors target the kinase domain directly:

• AZD8055: Dual mTORC1/2 inhibitor, activates autophagy more potently
• Torin 1: ATP-competitive inhibitor with broad mTOR inhibition
• INK128 (MLN0128): Brain-penetrant dual inhibitor

Advantages:

• More complete mTOR inhibition
• Avoids allosteric binding site issues
• Can inhibit both mTORC1 and mTORC2

Concerns:

• Greater toxicity with chronic use
• mTORC2 inhibition may impair neuroprotection

Combination Therapies

Given the complex pathophysiology of CBS/PSP, mTOR-targeted therapies may be most effective in combination:

• mTOR + anti-tau: Synergistic clearance of existing tau aggregates
• mTOR + autophagy enhancers: Additive effects on protein clearance
• mTOR + neurotrophic factors: Combined neuroprotective approaches
• mTOR + metabolic modulators: Addressing energy dysfunction

Clinical Considerations

Challenges in mTOR-targeted therapy for CBS/PSP[@crews2022]:

• Therapeutic window: Balancing autophagy induction with metabolic side effects
• Dosing strategy: Continuous vs. intermittent dosing approaches
• Biomarker development: Need for markers to monitor target engagement
• Patient selection: Identifying patients most likely to benefit
• Disease stage: Potential benefits may differ by disease stage

Current clinical trials are evaluating rapamycin and related compounds in neurodegenerative diseases, with results expected to inform future CBS/PSP trials.

Cross-Links to Related CBS/PSP Mechanisms

• [Autophagy Dysfunction in PSP](/mechanisms/autophagy-dysfunction-psp) — mTOR-mediated autophagy impairment
• [Lysosomal Dysfunction in PSP](/mechanisms/lysosomal-dysfunction-psp) — Downstream of mTOR dysregulation
• [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tau-cbs) — mTOR/tau interactions
• [Proteostasis in CBS/PSP](/mechanisms/cbs-proteostasis-network) — mTOR's role in protein quality control
• [Rapamycin for Tauopathy](/therapeutics/rapamycin-tauopathy) — Therapeutic targeting of mTOR
• [TFEB Activators](/therapeutics/tfeb-activators-neurodegeneration) — Complementary autophagy enhancement
• [Autophagy Enhancement](/therapeutics/autophagy-enhancement-tauopathy) — Combined approaches

References

[Laplante M, Sabatini DM, mTOR signaling in growth, metabolism, and disease (2012)](https://doi.org/10.1016/j.cell.2012.03.017)

[Oh WJ, Jacinto E, mTOR complex 2: signaling downstream of growth factor receptors (2011)](https://doi.org/10.1016/j.cellsig.2011.02.002)

[Rubinsztein DC, et al, Autophagy and neurodegeneration: clinical evidence (2015)](https://doi.org/10.1016/S1474-4422(15)00037-0)

[Hoeffer CA, Klann E, mTOR signaling: at the crossroads of plasticity, memory and disease (2010)](https://doi.org/10.1016/j.tins.2009.11.003)

[Ferrington RJ, et al, mTOR hyperactivity in tauopathies (2021)](https://doi.org/10.1186/s40478-021-01237-z)

[Nixon RA, The role of autophagy in neurodegenerative disease (2013)](https://doi.org/10.1038/nm.3232)

[Wang Y, Mandelkow E, Tau in physiology and pathology (2016)](https://doi.org/10.1038/nrn.2015.1)

[Stallings NR, et al, Rapamycin as a potential therapeutic treatment for tauopathies (2021)](https://doi.org/10.1007/s12031-020-01774-5)

[Crews L, et al, mTOR signaling in neurodegenerative disease: therapeutic implications (2022)](https://doi.org/10.1016/j.nbd.2022.105617)